       Document 0647
 DOCN  M95A0647
 TI    In vitro anti-HIV antibody production (IVAP) in HIV-infected children.
       American Pediatric Society 104th annual meeting and Society for
       Pediatric Research 63rd annual meeting; 1994 May 2-5; Seattle.
 DT    9510
 AU    Wang XP; Abrams E; Bamji M; Bakshi S; Paul M; Tetali S; Pahwa S; North
       Shore Univ. Hosp.-Cornell Univ. Med. College, Dept.; Pediatrics,
       Manhasset, NY, USA.
 SO    Pediatr AIDS HIV Infect. 1994 Oct;5(5):314 (unnumbered abstract). Unique
       Identifier : AIDSLINE AIDS/95330397
 AB    Timing of transmission and markers of disease progression are clinically
       important topics in HIV vertical transmission. In this study, IVAP (a
       revised method to exclude false positive results) was analyzed
       concurrently with virus culture, polymerase chain reaction (PCR) and
       clinical disease in 30 HIV-infected infants. All had 1st blood sample at
       age < 2 months and were followed for a minimum of 3 months (mean 12.5
       +/- 6.5 mo, range 3.0 to 25.0 mo) and had at least 2 follow up blood
       samples (mean 4.2 +/- 1.7, range 2 to 9 times). Mainly 3 patterns of
       IVAP response were observed: TABULAR DATA, SEE PUBLISHED ABSTRACT. Based
       on concurrent analyses of other laboratory and clinical data, our
       results suggest that 1) timing of a positive IVAP approximates time of
       in vivo seroconversion: for pattern I, IVAP became positive at a mean
       age of 6.4 +/- 3.0 mo (range 3.0-12.5 mo). 2) IVAP may serve as a marker
       for timing of HIV transmission, pattern I indicating transmission late
       in pregnancy or at birth and pattern III, early in-utero transmission.
       3) pattern II of IVAP was associated most frequently with positive HIV
       culture, positive PCR and rapid disease progression with AZT treatment.
 DE    Disease Transmission, Vertical  Human  HIV Antibodies/*BIOSYNTHESIS  HIV
       Infections/*IMMUNOLOGY  In Vitro  Infant  Polymerase Chain Reaction
       Support, U.S. Gov't, P.H.S.  MEETING ABSTRACT  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

